Comparative study of CA242 and CA19-9 in chronic pancreatitis

British Journal of Cancer

Volumn 73, Issue 3, 1996, Pages 372-376

  Furuya, N ^a   Kawa, S ^a   Hasebe, O ^a   Tokoo, M ^a   Mukawa, K ^a   Maejima, S ^a   Oguchi, H ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CA19 9; CA242; Chronic pancreatitis; Endoscopic retrograde choledocho pancreatography; Immunohistochemistry

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; TUMOR ANTIGEN;

ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CHRONIC PANCREATITIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PANCREAS CALCIFICATION; PANCREAS DUCT STENOSIS; PRIORITY JOURNAL;

EID: 0030044147     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.63     Document Type: Article

References (21)

1. ARENDS JW, VERSTYNE C, BOSMAN FT, HILGERS J AND STEPLEWSKI Z. (1983). Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: immunoperoxidase study. Hybridoma, 2, 219-229.
2. BANFI G, ZEBRI A, PASTORI S, PAROLINI D, DI CARLO V AND BONINI P. (1993). Behavior of tumor markers CA19-9, CA195, CAM43, CA242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin. Chem., 39, 420-423.
3. DEL VILLANO BC, BRENNAN S, BROCK P, BUCHER C, LIU V, MCCLURE M, RAKE B, SPACE S, WESTRICK B, SCHOEMAKER H AND ZURAWSKI JVR. (1983). Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA19-9. Clin. Chem., 29, 549-552.
4. HAGLUND C, LINDGREN J, ROBERTS PJ, KUUSELA P AND NORDLING S. (1989). Tissue expression of tumor associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA50 and CA19-9. Br. J. Cancer, 60, 845-851.
5. HAGLUND C, LUNDIN J, KUUSELA P AND ROBERTS PJ. (1994). CA242, a new tumour marker for pancreatic cancer: a comparison with CA19-9, CA50 and CEA. Br. J. Cancer, 70, 487-492.
6. JOHANSSON C, NILSSON O AND LINDHOLM L. (1991a). Comparison of serological expression of different epitopes on the CA50-carrying antigen, CanAg. Int. J. Cancer, 48, 757-763.
7. JOHANSSON C, NILSSON O, BAECKSTROEM D, JANSSON EL AND LINDHOLM L. (1991b). Novel epitopes on the CA50-carrying antigen: Chemical and immunochemical studies. Tumor Biol., 12, 159-170.
8. KAWA S, TOKOO M, HASEBE O, HAYASHI K, IMAI H, OGUCHI H, KIYOSAWA K, FURUTA S AND HOMMA T. (1994). Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br. J. Cancer, 70, 481-486.
9. KAWA S, TOKOO M, OGUCHI H, FURUTA S, HOMMA T, HASEGAWA Y, OGATA H AND SAKATA K. (1994b). Epitope analysis of Span-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas, 9, 692-697.
10. KOBAYASHI T, KAWA S, TOKOO M, OGUCHI H, KIYOSAWA K, FURATA S, KANAI M AND HOMMA T. (1991). Comparative study of CA50 (time-resolved fluoroimmunoassay), Span-1 and CA19-9 in the diagnosis of pancreatic cancer. Scand. J. Gastroenterol., 26, 787-797.
11. KUUSELA P, HAGLUND C AND ROBERTS PJ. (1991). Comparison of a new tumor marker CA242 with CA19-9, CA50 and carcinomembryonic antigen (CEA) in digestive tract disease. Br. J. Cancer, 63, 636-640.
12. LINDHOLM L, JOHANSSON C, JANSSON E-L, HALLBERG C AND NILSSON O. (1985). An immunometric assay (IRMA) for the CA50 antigen. In Tumor Marker Antigens, Holmgren J (ed.) p. 122. Student Litteratur: Lund, Sweden.
13. MAGNANI JL, NILSSON B, BROCKHAUS M, ZOPF D, STEPLEWSKI Z, KOPROWSKI H AND GINSBURG V. (1982). A monoclonal antibody-defined antigen associated gastrointestinal cancer is a ganglioside containing sialylated lact-N-fucopentaose II. J. Biol. Chem., 257, 14365-14369.
14. MALESCI A, TOMMASINI MA, BONATO C, BOCCHIA P, BERSANI M, ZERBI A, BERETTA E AND DI CARLO V. (1987). Determination of CA19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology, 92, 60-67.
15. NILSSON O, MANSSON JE, LINDHOLM L, HOLMGREN J AND SVENNERHOLM L. (1985). Sialyllacttetraosylceramide, a novel ganglioside antigen detected in human carcinoma by monoclonal antibody. FEBS Lett., 182, 398-402.
16. NILSSON O, JOHANSSON C, GLIMELIUS B, PERSSON B, PEDERSON NA, SANDBERG A AND LINDHOLM L. (1992). Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA19-9. Br. J. Cancer, 65, 215-221.
17. PASANEN PA, ESKELINEN M, PARTANEN K, PIKKARAINEN P, PENTTILA I AND ALHAVA E. (1992). Clinical evaluation of a new serum tumor marker CA242 in pancreatic carcinoma. Br. J. Cancer, 65, 731-734.
18. ROTHLIN MA, JOLLER H AND LARGIADER F. (1993). CA242 is a new tumor marker for pancreatic cancer. Cancer, 71, 701-707.
19. SATOMURA Y, SAWABU N, TAKEMORI Y, OHTA H, WATANABE H, OKAI T, WATANABE K, MATSUNO H AND KONISHI F. (1991). Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues. Pancreas, 4, 448-458.
20. TABUCHI Y, DEGUCHI H AND SAITOH Y. (1988). Carcinoembryonic antigen and carbohydrate antigen CA19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Cancer, 62, 1605-1613.
21. TATSUTA M, YAMAURA H, ISHII H, ICHII M, NOGUCHI S, YAMAMOTO R AND OKUDA S. (1985). Values of CA19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer, 56, 2669-2673.